Core Viewpoint - Addex Therapeutics has regained all development and commercialization rights to ADX71149 (JNJ-40411813) after the termination of its partnership with Janssen Pharmaceuticals, allowing the company to explore new therapeutic indications and potential partnerships for the drug [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2]. - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2]. - Addex also has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [2]. - The company holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [2]. Recent Developments - The termination of the partnership with Janssen Pharmaceuticals allows Addex to regain control over ADX71149, which has completed three Phase 2 studies and possesses a high-quality data package [2]. - The CEO of Addex expressed excitement about regaining control and mentioned ongoing evaluations for high-value therapeutic indications and discussions with potential partners [2].
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149